Pancreatic Cancer Research

ResearcherCleveland ClinicActive in the last 2 years

Jeffrey M. Hardacre

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111644986, A5158641335. Sources: OpenAlex.

Their work

Papers
29 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 7 papers · 2022: 6 papers · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 29

  1. Pancreatic Cancer: Genetics, Screening, Prevention, and Treatment. First author DOI 10.1016/j.suc.2026.03.009↗
  2. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  3. Understanding surgical attrition for "resectable" pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.11.008↗
  4. To Revise or Not Revise? Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15616-y↗
  5. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  6. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.03.011↗
  7. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14221-9↗
  8. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Co-author DOI 10.1016/j.amjsurg.2021.10.001↗
  9. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Co-author DOI 10.1016/j.hpb.2021.08.938↗
  10. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Co-author DOI 10.1016/j.hpb.2021.12.014↗
  11. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  12. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2022.03.013↗
  13. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗
  14. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1002/cnr2.1390↗
  15. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2020.11.035↗
  16. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… Co-author DOI 10.1016/j.surg.2020.12.003↗
  17. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2021.0003↗
  18. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  19. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.1245/s10434-020-08859-y↗
  20. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  21. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. First author DOI 10.1002/jso.26196↗
  22. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Co-author DOI 10.18632/oncotarget.27727↗
  23. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  24. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2017.10.011↗
  25. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  26. Completion Pancreaticoduodenectomy for a Second Primary Pancreatic Cancer: A Case Report. Co-author DOI 10.1089/crpc.2016.0010↗
  27. Surgery for Localized Pancreatic Cancer: The Trend Is Not Improving. Co-author DOI 10.1097/mpa.0000000000000511↗
  28. Trends in the treatment of resectable pancreatic adenocarcinoma. Last author DOI 10.1007/s11605-013-2335-x↗
  29. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. Co-author DOI 10.1007/s11605-012-2064-6↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Brian Ammori · 22 shared papers, 2014–2024 · strength 3.16
  2. Jordan Michael Winter · 18 shared papers, 2020–2024 · strength 2.72
  3. Lee Mayer Ocuin · 17 shared papers, 2020–2024 · strength 2.62
  4. Jonathan J. Hue · 15 shared papers, 2020–2024 · strength 2.27
  5. Luke Daniel Rothermel · 13 shared papers, 2020–2023 · strength 1.90
  6. Kavin Sugumar · 12 shared papers, 2021–2023 · strength 1.82
  7. Mohamedraed Elshami · 7 shared papers, 2022–2024 · strength 1.22
  8. David Lawrence Bajor · 7 shared papers, 2020–2023 · strength 0.95
  9. Sami O. Abul-Khoudoud · 1 shared paper, 2026 · strength 0.63
  10. Sarah Coseo Markt · 4 shared papers, 2021–2022 · strength 0.56
  11. Richard S. Hoehn · 3 shared papers, 2022–2024 · strength 0.53
  12. Elena Gabriela Chiorean · 5 shared papers, 2013–2026 · strength 0.41
  13. Andrew H. Ko · 4 shared papers, 2017–2026 · strength 0.38
  14. Brian G. Czito · 4 shared papers, 2017–2026 · strength 0.38
  15. Noelle K. LoConte · 4 shared papers, 2017–2026 · strength 0.38
  16. Robert A. Wolff · 4 shared papers, 2017–2026 · strength 0.38
  17. Courtney L. Scaife · 4 shared papers, 2017–2026 · strength 0.38
  18. Eric K. Nakakura · 4 shared papers, 2017–2026 · strength 0.38
  19. Mokenge Peter Malafa · 4 shared papers, 2017–2026 · strength 0.38
  20. Brian Matthew Wolpin · 4 shared papers, 2017–2026 · strength 0.38
  21. Dana Backlund Cardin · 4 shared papers, 2017–2026 · strength 0.38
  22. Mary E. Dillhoff · 4 shared papers, 2017–2026 · strength 0.38
  23. Andrew M. Lowy · 4 shared papers, 2017–2026 · strength 0.38
  24. Vincent M. Chung · 4 shared papers, 2017–2026 · strength 0.38
  25. Al B. Benson · 4 shared papers, 2017–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.